The Effects of Resveratrol Supplementation on Cognition, Cerebral Blood Flow, Microbiota and Systemic Inflammation.

The Acute and Chronic Effects of Resveratrol Supplementation on Cognitive Function, Gastrointestinal Microbiota and Cerebral Blood Flow: a Double-blind, Placebo-controlled, Parallel-groups Study in Healthy, Overweight Humans.

Previous research shows that a diet high in fat has harmful effects on gut health. This increases the chance of developing obesity-related diseases (such as type 2 diabetes) and disrupts cognition and mood.

Research has suggested that gut health can be improved by taking certain supplements, including resveratrol (a polyphenol found primarily in red grape skins). Resveratrol has also been shown to improve brain blood flow and possibly brain function - however, there is limited research studying this.

This study will investigate the effects of 12 weeks daily consumption of resveratrol on cognitive function, cerebral blood flow, gut microbiota and systemic inflammation in overweight and obese healthy adults.

Study Overview

• Status: Completed
• Conditions: Cerebral Blood Flow; Overweight and Obesity; Systemic Inflammation; Gut Microbiota; Cognitive Function and Mood
• Intervention / Treatment: Dietary supplement: Resveratrol; Dietary supplement: Placebo

Detailed Description

Each participant will be required to attend the laboratory on four occasions. The first of these will be an initial screening/training visit, this will take place in the afternoon and last 3 hours in total. During the initial visit participants will be asked to provide written informed consent. They will provide lifestyle and demographic data and screened regards to physical health (height, weight, blood pressure, waist to hip ratio). They will then be trained on the computerised cognitive and mood tasks. At the end of the appointment they will be provided with a food diary and a stool sample collection kit.

Study days 1 and 2 (12 weeks apart) :

Participants will arrive at the laboratory at 8.00am having fasted from 8pm the previous evening, avoided caffeinated products for 18 hours, alcohol and over the counter medication for 24 hours and oral antihistamines for 48 hours prior to the session commencing. They will also bring with them their completed food diary and stool sample.

Participants will provide a blood sample and then will be given a standardised breakfast of x2 slices of white toast with butter and a decaf tea or coffee. They will also provide a urine sample. Participants will then complete a computerised cognitive assessment (~1 hour in length), followed by measurements of blood pressure and heart rate. Participants in the sub-sample who will also provide brain (cerebral) blood flow data, will then have the quantitative near-infrared spectroscopy (qNIRS) headband fitted across the forehead and a 5 minute baseline measure will be recorded.

Following this the participants will consume their treatment for the day, followed by a short break and then will complete the second cognitive assessment. The qNIRS participants will again provide brain blood flow data and following that will be provided with a standardised lunch (cheese sandwich, ready salted crisps and a custard pot). Participants will complete their final cognitive assessment and will then provide a second blood sample.

At the end of the first study day participants will be provided with their treatment and treatment diary, they will be instructed to take one tablet twice a day (with breakfast and dinner). Both study days will be identical and will take place 84 days (+/- 5 days) apart.

Participants are also required to attend a short treatment exchange visit during Week 6 (5 minutes).

• Study Type: Interventional
• Enrollment (Actual): 110
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United Kingdom
  • Tyne And Wear
    • Newcastle Upon Tyne, Tyne And Wear, United Kingdom, NE1 8ST
      • Northumbria University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 31 years to 56 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Interested in taking part in the study
• Healthy
• Aged 35-60 years (inclusive)
• Have a BMI of between 25-39.9
• Willing to consume your normal diet during the 12 week supplementation period

Exclusion Criteria:

You should not take part if you:

• Are aged under 35 or over 60
• Have a Body Mass Index (BMI) lower than 25 or higher than 39.9.
• Have taken antibiotics (including pre- and pro-biotic supplements/drinks) during the previous 8 weeks
• Have irregular bowel movements (less than 1 per day)
• Have any pre-existing medical conditions/illness with some exceptions - please check with the researcher
• Have type 1 or type 2 diabetes
• Are currently taking prescription medications with some exceptions- please check with the researcher
• Have a visual impairment that cannot be corrected by glasses or contact lenses, including colour blindness.
• English is not your first language or your English proficiency is not equivalent to the International English language test system (IELTS) band 6 or above
• Have any learning difficulties or dyslexia
• Currently suffer from frequent migraines that require medication (>1 per month)
• Have any food allergies, intolerances or sensitivities
• Have high blood pressure (systolic over 159 mm Hg or diastolic over 99 mm Hg)
• Smoke
• Have a history of alcohol or drug abuse
• Are pregnant, seeking to become pregnant or lactating
• Are unable to complete all of the study assessments
• Are currently participating in any other clinical or nutritional intervention study, or have done within the past 4 weeks
• Have any health condition that would prevent fulfilment of the study requirements
• Have habitually used supplements within the last month (defined as more than 3 consecutive days or 4 days in total)
• Have an excessive caffeine intake (>500mg per day) - equivalent to 5/6 cups of coffee/8 cups of tea per day or equivalent from other sources
• Consume more than 5 portions of fruit or vegetables per day
• Any sleep disturbances or take sleep aid medication
• Have any known active infections
• You have or may think you are at risk of having syphilis, hepatitis, the Human T - lymphotropic virus or the Human Immunodeficiency Virus?
• You have ever had breast cancer and/or a mastectomy
• You have haemophilia or any similar clotting disorder
• Do not have a bank account (required for payment)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo; Matched placebo capsules (1 capsule consumed at two timepoints each day).	Dietary supplement: Placebo; Participants will consume one of the treatment types daily for a period of three months.
Experimental: Resveratrol; 500mg of Veri-te Resveratrol (consumed as two 250mg tablets, at two timepoints each day).	Dietary supplement: Resveratrol; Participants will consume one of the treatment types daily for a period of three months.; Other Names: Veri-teTM Resveratrol

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline cognitive (memory) performance at 45 minutes, 240 minutes and 12 weeks post dose	Memory performance will be assessed using a computerised cognitive battery (administered using COMPASS cognitive assessment program). Memory will be assessed using 3 global measures (Working memory, speed of memory and episodic memory). The global measures are created by taking data from several tasks targeting that cognitive domain. Working memory: a combined accuracy score (% correct) from the tasks: numeric working memory (NWM), serial 3's subtractions (SS3), serial 7's subtractions (SS7) and rapid visual information processing (RVIP). Speed of memory: a combined speed score (msecs) from tasks NWM, delayed name to face recall, delayed picture recognition and delayed word recognition. Episodic memory: a combined accuracy score (% correct) from tasks immediate word recall, delayed word recall, delayed name to face recall, delayed picture recognition, delayed word recognition.	45 minutes, 240 minutes, 12 weeks
Change from baseline cognitive (Attention) performance at 45 minutes, 240 minutes and 12 weeks post dose	Attention performance will be assessed using a computerised cognitive battery (administered using COMPASS cognitive assessment program). Attention will be assessed using 2 global measures (Accuracy of Attention and Speed of Attention). Accuracy of Attention: accuracy score (% correct) from choice reaction time task. Speed of attention: speed score (msecs) taken from choice reaction time task.	45 minutes, 240 minutes, 12 weeks
Gut microbiota	Changes in gut microbiota communities, quantified using 16S ribosomal ribonucleic acid (rRNA) gene community analysis.	12 weeks
Change from baseline systemic inflammatory cytokines	Inflammatory cytokines (including C-reactive protein and Interleukin-6) will be measured in plasma using ELISA analysis, in association with other endpoints including resveratrol metabolites.	5 hours, 12 weeks
Change from baseline urinary and plasma metabolome	Changes in plasma and urinary metabolome will be profiled using a Thermo Q-Exactive liquid chromatography/mass spectrometry spectrometer and data analysed using Progenesis QI.	12 weeks
Change from baseline total haemoglobin cerebral blood flow (CBF) measurement	CBF of the frontal cortex measured using quantitative near infrared spectroscopy (q-NIRS).	115-190 minutes, 12 weeks
Change from baseline deoxygenated haemoglobin CBF measurement	CBF of the frontal cortex measured using qNIRS.	115-190 minutes, 12 weeks
Change from baseline oxygen saturation CBF measurement	CBF of the frontal cortex measured using qNIRS.	115-190 minutes, 12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline Blood Pressure	Systolic and diastolic blood pressure will be taken after each cognitive assessment (measured in mm Hg).	45 minutes, 240 minutes, 12 weeks
Change from baseline Heart Rate	Heart rate will be measured after each cognitive assessment (measured in BPM).	45 minutes, 240 minutes, 12 weeks
Change from baseline subjective mood score	Subjective mood scores will be measured using the Profile of Mood scale. The questionnaire includes 65 items and participants rate their mood on a scale of 0-4 (not at all - extremely). These scores are collapsed into 6 mood outcomes (Tension, depression, anger, vigour, fatigue and confusion) and a total mood disturbance score.	240 minutes, 12 weeks
Weight change and BMI	Change in weight and BMI between visits	12 weeks

Collaborators and Investigators

• Sponsor: Northumbria University
• Collaborators: Evolva SA
• Investigators: Principal Investigator: Emma Wightman, Dr, Northumbria University

Study record dates

Study Major Dates

• Study Start (Actual): February 6, 2018
• Primary Completion (Actual): July 13, 2019
• Study Completion (Actual): July 13, 2019

Study Registration Dates

• First Submitted: February 7, 2018
• First Submitted That Met QC Criteria: February 21, 2018
• First Posted (Actual): February 27, 2018

Study Record Updates

• Last Update Posted (Actual): March 17, 2020
• Last Update Submitted That Met QC Criteria: March 16, 2020
• Last Verified: March 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Body Weight; Inflammation; Overweight; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Platelet Aggregation Inhibitors; Protective Agents; Antioxidants; Resveratrol
• Other Study ID Numbers: 52P6

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No